Ulcefate

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ulcefate

Quick Facts: Ulcefate (Sucralfate)

Property Description
Active Ingredient Sucralfate (Basic aluminum salt of sucrose octasulfate)
Form Tablets, Oral Suspension, Granules for Oral Suspension
Pharmacological Class Gastrointestinal Agent, Cytoprotective Antiulcer Agent
General Purpose Provides mucosal protection and supports tissue healing
Origin Synthetic Compound

What Type of Medicine is Ulcefate (Sucralfate)?

Ulcefate is a prescription-only medication primarily categorized as a Gastrointestinal Agent and a Cytoprotective Antiulcer Agent. Its core function is dedicated to providing physical defense for the gastrointestinal lining. This classification highlights its unique mode of action, which is distinct from acid-reducing treatments, such as proton pump inhibitors, which act systemically to decrease acid secretion. The Sucralfate formulation is utilized for its localized efficacy in protecting the mucosal layer. As a single-ingredient product, its therapeutic strategy is singularly focused on fostering a healing environment directly at the site of damage, a feature differentiating it from combination gastrointestinal treatments.


Composition and Physical Form of Sucralfate

The active substance in Ulcefate is Sucralfate, a synthetic compound known chemically as the basic aluminum salt of sucrose octasulfate. This highly organized chemical structure is critical to the drug’s localized function. Sucralfate is administered via the oral route and is available as tablets, an oral suspension, and granules for oral suspension. This variety of forms ensures the active substance can be effectively delivered directly to the target tissue along the digestive lining. The non-systemic nature of the drug—meaning it acts locally rather than being absorbed into the bloodstream—is a direct result of its unique salt composition.


The General Purpose of This Mucosal Protective Agent

The general purpose of this medication is to shield the gastrointestinal lining and promote recovery by establishing a physical barrier. When the Sucralfate compound encounters the acidic environment of the stomach, it activates, forming a durable, polymer-like substance that strongly adheres to the proteins of damaged tissue. This barrier resists attack from corrosive stomach contents, including digestive enzymes like pepsin and harmful bile salts, thereby promoting tissue integrity and natural healing. This protective coating acts to physically protect the vulnerable mucosal layer against continuous chemical and enzymatic assault.

What side effects are possible with Ulcefate?

Possible Side Effects and Safety Information

Ulcefate (sucralfate) is generally well-tolerated, as it is minimally absorbed into the bloodstream and acts locally in the gastrointestinal tract. However, like all medications, it can cause side effects.

Constipation is the most common side effect, reported in up to 10% of patients. Other relatively common side effects that may occur include:

  • Dry mouth
  • Nausea, vomiting, or gas (flatulence)
  • Indigestion or upset stomach
  • Headache or dizziness
  • Sleep problems (insomnia)
  • Back pain

Serious Side Effects and Warnings

While rare, serious side effects can occur. Seek immediate medical attention if you experience signs of a severe allergic reaction, such as hives, rash, itching, swelling of the face, throat, or tongue, or difficulty breathing.

There is a low risk of bezoar formation (a hard mass of undigested material) in patients with conditions like delayed gastric emptying, or those receiving enteral tube feedings. Patients with chronic renal (kidney) impairment or those on dialysis should use Ulcefate with caution, as it contains aluminum, which can accumulate in the body and potentially lead to aluminum toxicity.

Ulcefate can interact with other medications by potentially decreasing their absorption. To minimize this risk, most other oral medications should be taken at least two hours before or after an Ulcefate dose. This includes certain antibiotics (e.g., fluoroquinolones), digoxin, phenytoin, and thyroid hormones. Antacids should be separated by at least 30 minutes. Always consult a healthcare provider about all current medications.

Overdose and Emergency Response

The official regulatory profile for Sucralfate overdose indicates a minimal risk associated with acute oral overdosage. This classification is due to the drug being only minimally absorbed into the bloodstream following oral administration. In rare reports of acute overdosage, most patients remained asymptomatic. When symptoms did occur, they were generally confined to mild gastrointestinal complaints, including nausea, vomiting, dyspepsia, and abdominal pain.

Management of overdosage is classified as symptomatic and supportive, as official regulatory documents state that no specific antidote is known.

When to Seek Immediate Medical Help

Immediate emergency medical attention must be sought if a severe manifestation is suspected. Regulator-mandated triggers include if the individual has collapsed, experiences a seizure, has trouble breathing, or cannot be awakened. Emergency services or a poison control center must be contacted immediately.

Population-Specific Overdose Considerations

A specific, severe risk is documented for patients with chronic renal failure or those receiving dialysis. These individuals face an elevated risk of aluminum accumulation and subsequent toxicity, which may include osteodystrophy and encephalopathy. This risk is directly related to the Sucralfate formulation's aluminum content and the patient's impaired ability to excrete the absorbed portion.

Therapeutic Uses of Ulcefate

What Ulcefate Treats: Main Uses and Benefits

Ulcefate is a medication primarily used to manage and treat gastrointestinal conditions related to acid-induced damage in the digestive tract. It belongs to a class of medications known as cytoprotective agents, which work differently than antacids or acid suppressants.

Primary Indications

The medication is most commonly utilized for the following conditions:

  • Active Duodenal Ulcers: It is used for the short-term treatment of open sores that form in the upper part of the small intestine (the duodenum).
  • Maintenance Therapy: It may be used in lower doses to prevent the recurrence of duodenal ulcers after the initial sores have healed.
  • Gastric Ulcers: It is sometimes employed to treat ulcers located in the stomach lining.
  • Gastritis: It can help manage inflammation of the stomach lining by providing a protective barrier against gastric acid and pepsin.

Mechanism of Action and Benefits

Unlike medications that reduce the production of stomach acid, Ulcefate works by creating a physical barrier over damaged tissue.

  • Protective Coating: Upon entering the acidic environment of the stomach, the medication forms a viscous, paste-like substance that binds selectively to the proteins on the surface of an ulcer. This creates a protective seal.
  • Prevention of Further Irritation: By coating the ulcer site, it shields the damaged tissue from the erosive effects of stomach acid, bile salts, and digestive enzymes like pepsin.
  • Support for Natural Healing: By isolating the ulcer from irritants, the medication provides an environment where the body's natural healing processes can occur more effectively.
  • Local Action: The medication is minimally absorbed into the bloodstream, meaning its therapeutic effects are concentrated locally at the site of the gastrointestinal injury.

Regulatory References

  1. NIH DailyMed Overview of Sucralfate Indications

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Ulcefate (Sucralfate)

This eligibility profile is based strictly on official government regulatory documents, such as Prescribing Information and SmPC equivalents.

Absolute Exclusion (Contraindications)

Ulcefate must not be used by patients with a known hypersensitivity reaction to the active substance (sucralfate) or to any of the product's excipients.

Conditional or Restricted Use

Population/Condition Regulatory Status
Chronic Renal Failure/Dialysis Use with caution due to the risk of aluminum accumulation and toxicity.
Pregnant Women Conditional use (Category B); administer only if clearly needed due to a lack of adequate human studies.
Nursing Mothers Caution should be exercised as it is not known whether the drug is excreted in human milk.

Use Not Established

Pediatric Use: The safety and effectiveness have not been established in pediatric patients.

Geriatric Use: Although generally eligible, caution is advised in older adults due to the increased likelihood of decreased renal function and coexisting health conditions.

This structure defines eligibility based on absolute exclusions for allergy, conditional use for co-morbidities like renal impairment, and limitations due to the absence of established safety data in the pediatric population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ulcefate’s official interaction profile is defined by its non-systemic, localized action, which results in two primary, officially documented interaction types. There are no explicitly listed contraindicated combinations in key regulatory labeling.

The most common interaction is a pharmacokinetic interaction where Ulcefate physically binds to co-administered oral medications in the gastrointestinal tract, leading to their reduced systemic absorption and consequently a decreased plasma concentration (exposure). To mitigate this effect, regulatory labeling mandates specific timing separation for numerous drugs.

Interacting Substance Class Required Timing Rule
Thyroid Hormones (e.g., Levothyroxine) Must be administered 4 hours apart.
Fluoroquinolones, Digoxin, Warfarin, Phenytoin, H2-Antagonists Must be administered 2 hours apart.
Aluminum-containing Antacids Must be administered 30 minutes apart.

A secondary pharmacodynamic interaction involves the aluminum component of Ulcefate. Co-administration with other aluminum-containing products increases the total systemic aluminum burden. This interaction is officially noted as a specific concern for patients with chronic renal failure, who have impaired aluminum clearance and are at a higher risk of aluminum accumulation. No specific interaction rules are documented for alcohol, food, or general herbal products.

Mechanism of Action

The mechanism of Ulcefate (Sucralfate) is entirely localized and cytoprotective, relying on a unique physicochemical reaction to isolate damaged gastrointestinal tissue, facilitating its structural restoration without systemic absorption.


Acid-Activated Barrier and Selective Adhesion

The drug's function begins when it encounters the acidic environment of the stomach ( pH < 4), which triggers its dissociation and transformation into a highly charged, viscous polymer. This polymer exhibits a strong, selective affinity for the exposed proteins (like fibrin) at the base of damaged tissue, forming a stable, **non-absorbable physical barrier. This activation relies entirely on the acidic environment for the necessary polymerization step.


Physical Defense and Inactivation of Corrosive Agents

Once adhered, the polymer shield provides cytoprotection by physically blocking the tissue from contact with stomach acid ( HCl) and neutralizing other corrosive contents. Specifically, the barrier functions to adsorb and inactivate the protein-degrading enzyme pepsin and harmful bile salts, thereby interrupting the sequence of localized chemical damage. This continuous defense mechanism results in a stable physiological environment where tissue regeneration is supported by the resulting physiological environment.


Modulation of Local Healing Factors

Beyond physical shielding, Sucralfate's mechanism extends to supporting the body's natural restorative processes. The barrier helps to retain and concentrate local epithelial growth factors ( EGF) while stimulating the synthesis and release of protective mediators, including prostaglandins ( PGE2) and bicarbonate ( HCO3^-). This results in enhanced mucosal blood flow and increased local pH buffering, supporting the structural integrity of the mucosa.

Dosage and Administration Information

How to Use Ulcefate (Sucralfate): Administration Guidelines

The usage of Ulcefate is governed by a time-dependent protocol that defines the dose, frequency, and timing relative to food and other substances.

Category Instruction (Label-Based)
Route of administration Oral administration only. The liquid suspension is explicitly not for intravenous use.
Dosing schedule Active Treatment: 1 gram four times daily (QID). Maintenance: 1 gram twice daily (BID).
Timing in relation to meals Must be taken on an empty stomach: 1 hour before or 2 hours after meals, and at bedtime.

Key Procedural Conditions

  • Antacid and Drug Separation: Antacids must be separated from a Ulcefate dose by at least 30 minutes. Most other oral medications require administration 2 hours before or after Sucralfate to prevent alterations in drug absorption.
  • Preparation: If using the oral suspension, it must be thoroughly shaken before measuring. Tablets may be dispersed in a small amount of water for easier administration.
  • Duration: Active treatment for an ulcer is typically continued for 4 to 8 weeks. Maintenance therapy for prophylaxis may be continued for up to 1 year.

Population-Specific Usage

For older adults, dose selection should be cautious, starting at the low end of the dosing range, with consideration for renal function monitoring. For patients with existing renal impairment, use is cautioned due to the risk of aluminum accumulation. Safety and efficacy have not been established for pediatric patients.

Recent Clinical Evidence

Evidence for Use in Healing and Maintaining Ulcer Status

Research has primarily examined ulcer status in adult patients with active duodenal and gastric ulcers using short-term Randomized Controlled Trials (RCTs). These studies explored how quickly the ulcers reached an endpoint status, often comparing Ulcefate against a placebo or other treatments. Ulcefate was also studied for long-term maintenance after ulcers have successfully healed. These studies, typically double-blind and placebo-controlled, focused on outcomes related to ulcer recurrence rates over an intermediate-term observation period (up to 12 months). The results apply only to the studied populations during these short-term or intermediate periods, and there is limited information for long-term outcomes exceeding one year.


Studies in Specialized Critical Care Settings

Ulcefate was evaluated in research exploring temporary physiological imbalance in critically ill adult patients where stress ulcer prophylaxis was monitored. The evidence consists mainly of Systematic Reviews and Meta-analyses of randomized trials. These studies explored outcomes monitoring physiological strain or stress, specifically measuring incidence of clinically important gastrointestinal bleeding and Ventilator-Associated Pneumonia (VAP). Findings were mixed, and the certainty remains low for some studies due to high variation in study designs and patient populations.


Evidence Gaps and Follow-up Limitations

The majority of the evidence comes from trials observing responses over defined time intervals, meaning follow-up durations were limited. Long-term effects are not fully established regarding the durability of the local activity or sustained prevention of ulcer recurrence over many years. Furthermore, data for certain groups remain insufficient. For example, limited evidence exists for Ulcefate in pediatric populations compared to the adult data. Finally, research has gaps where limited comparative evidence exists when studies examined Ulcefate against other therapeutic agents.

Key Studies & References

  1. Sucralfate Oral Suspension and Tablet Prescribing Information (FDA Approved Drug Products and DailyMed Monograph)

Frequently Asked Questions (FAQ)

Common questions about Ulcefate (FAQ)


Q: What is Ulcefate actually used for?

A: Ulcefate is indicated for the short-term treatment of an active duodenal ulcer. The official labeling also includes approval for its use as maintenance therapy to help prevent the recurrence of duodenal ulcers once they have healed. This information is based on controlled clinical trials reviewed by regulatory bodies.

Q: Is Ulcefate considered an antacid?

A: Regulatory documents classify Ulcefate as an antiulcer or cytoprotective agent, meaning it works primarily by protecting tissue. Its main function is to form a physical barrier over the ulcer site, although it also possesses minimal acid-neutralizing capacity.

Q: What research supports the use of Ulcefate?

A: The regulatory approval for Ulcefate is based on controlled clinical trials that demonstrated its effectiveness in the healing of duodenal ulcers compared to placebo. These studies provide the evidence base for its approved indications.

Q: Is Ulcefate only for the stomach or also the intestines?

A: Official information indicates that Ulcefate is approved for treating duodenal ulcers. The duodenum is the first section of the small intestine, located just after the stomach. Its protective action is therefore focused on this specific area of the gastrointestinal tract.

Q: How quickly should Ulcefate start working after I take it?

A: The action of Ulcefate involves a chemical reaction that creates a protective paste or coating. Based on the drug’s pharmacological data, the formation of this barrier is typically achieved within 1 to 2 hours after administration.

Q: What kind of side effects are common with Ulcefate?

A: According to the official product information, the most commonly reported side effect in clinical trials is constipation. Other infrequent adverse effects reported include dry mouth, nausea, dizziness, and headache.

Q: Is it normal to feel a bit constipated when taking Ulcefate?

A: Constipation is the most frequently reported adverse reaction associated with Ulcefate use. In clinical trials, this side effect was reported by a small percentage of patients (around 2%).

Q: Are there any serious side effects to look out for with Ulcefate?

A: Rare, serious events have been reported in postmarketing surveillance. These include hypersensitivity reactions (like rash or swelling) and the formation of bezoars (a mass in the stomach), particularly in patients with predisposing medical conditions.

Q: Can Ulcefate cause stomach pain?

A: Gastric discomfort or abdominal pain has been reported as an infrequent adverse effect in regulatory documents.

Q: Can Ulcefate cause dry mouth?

A: Dry mouth is listed in regulatory documents as an infrequent adverse effect related to the gastrointestinal system.

Q: Can Ulcefate cause drowsiness?

A: The regulatory listing of adverse effects includes drowsiness and sleepiness as nervous system effects, although these were reported in less than 0.5% of patients in clinical trials.

Q: Does Ulcefate cause diarrhea?

A: Diarrhea is listed among the adverse reactions reported in regulatory documents. It was noted to occur in less than 0.5% of patients in clinical trials, making it a less common side effect than constipation.

Q: What should I do if I get a rash after taking Ulcefate?

A: Rash and other signs of hypersensitivity reactions, such as itching or swelling, have been reported. These are considered adverse events noted in regulatory reports.

Q: Can Ulcefate be taken long-term?

A: Treatment for an active ulcer is typically limited to 4 to 8 weeks. Regulatory labeling does include approved instructions for a maintenance therapy dosage, which may be continued for longer periods after the ulcer has healed.

Q: Do studies show Ulcefate is helpful for long-term stomach issues?

A: Regulatory labeling indicates that Ulcefate is approved for maintenance therapy following the healing of acute duodenal ulcers. This suggests that the drug is recognized for managing long-term ulcer recurrence.

Q: Is Ulcefate safe to use if I have kidney problems?

A: Official warnings note that Ulcefate should be used with caution in patients with chronic renal failure or those undergoing dialysis. This is due to the potential risk of aluminum accumulation in the body.

Q: Does Ulcefate contain aluminum?

A: Regulatory information describes sucralfate (the active ingredient in Ulcefate) as an aluminum complex. Caution is advised for patients with existing kidney impairment due to the risk of aluminum accumulation.

Q: Does Ulcefate affect blood pressure medication?

A: Regulatory information notes that Ulcefate can reduce the extent of absorption (bioavailability) of several other medications when administered simultaneously. Separation of dosing is generally recommended to manage this potential interaction and prevent alterations in the other drug's absorption.

Q: Is Ulcefate known to interact with thyroid medicine?

A: Regulatory warnings specifically note that Ulcefate may reduce the absorption of L-Thyroxine (a thyroid medication). Separation of administration by at least 2 hours is outlined as a measure to prevent this.

Q: Does Ulcefate interact with pain relievers like ibuprofen?

A: The general drug interaction warning applies to many oral medications, stating that Ulcefate can reduce the absorption of other oral medications. Therefore, separation of dosing by two hours is typically recommended.

Q: Are there any foods or drinks I need to avoid while on Ulcefate?

A: Regulatory labeling requires Ulcefate to be taken on an empty stomach, separated from meals. Beyond this required timing, the labeling does not list specific foods or drinks that must be entirely avoided.

Q: Do you need a prescription for Ulcefate?

A: Yes, Ulcefate is classified as a prescription-only medication. It requires a prescription from a licensed healthcare provider.

Q: Are there generic versions of Ulcefate available?

A: Yes, regulatory information confirms that generic versions of the active ingredient, sucralfate, are available.

Q: How is Ulcefate different from Sucralfate?

A: Sucralfate is the approved active ingredient of the medication. Ulcefate is the brand name under which the product is marketed.

Q: What are the ingredients in Ulcefate?

A: The active ingredient is sucralfate. Regulatory labeling also lists the various inactive ingredients (excipients) used in the formulation of the tablets or liquid suspension.

Q: Can children or teenagers be prescribed Ulcefate?

A: According to official product information, the safety and effectiveness of Ulcefate in pediatric patients have not been established in the clinical trials reviewed for regulatory approval.

Q: Can Ulcefate be mixed with water before taking?

A: Regulatory documents state that Ulcefate tablets may be dispersed in a small amount of water to assist with administration.

Q: Is it okay to crush or chew Ulcefate tablets?

A: Official labeling states that Ulcefate tablets may be dispersed in a small amount of water for easier administration. The labeling does not contain specific instructions regarding crushing or chewing the tablets.

How should Ulcefate be stored and disposed of?

How to Store and Dispose of Ulcefate (Sucralfate)

The official labeling for Ulcefate defines strict conditions for its storage and disposal.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature between 20°C and 25°C (68°F and 77°F).
Protection Keep the medicine away from excess heat, moisture, and direct light.
Container Keep the medicine in its container and ensure it is tightly closed.
Handling The oral suspension must not be frozen. Shake well before use.
Safety Always keep Ulcefate out of the reach of children.

Disposal Instructions

Do not keep medicine that is outdated or no longer needed. Unused or expired Ulcefate should be disposed of by following official guidelines. The FDA recommends using a drug take-back program if one is available. Otherwise, mix the medication with an undesirable substance, place it in a sealed container, and throw it in the household trash. Do not flush it down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ulcefate found in:

A-Z Index: